Biotechnology from bench to business

• Follow GEN on:
• Log In / Register | Subscribe

Current Issue

Top Keywords

• ADME/Tox
• Angiogenesis
• Apoptosis
• Antibodies
• Biomanufacturing
• Biomarkers
• Bioproduction Disposables
• Bioreactors
• Biosimilars
• Biotherapeutics
• Cancer
• Cancer Stem Cells
• Cell Culture
• Cell Signaling
• Cell-Based Assays
• Cellular Analysis
• CGH
• Depression
• DNA Methylation
• Embryonic Stem Cells
• Epigenetics
• FDA
• Gene Expression
• Genetics
• Genomics
• Glycan Analysis
• HPLC
• Immunoassay
• In Vitro Diagnostics
• In Vivo Imaging
• Liquid Handling
• mAb Production
• Metabolic Diseases
• Microarrays
• miRNA
• Molecular Diagnostics
• Multiplexing
• Nanotechnology
• Next-Generation Sequencing
• Pathway Analysis
• Peptide Therapeutics
• Pharmacokinetics
• PCR
• Protein Characterization
• Protein Expression
• Protein Production
• Protein Therapeutics
• qPCR
• Reagents
• Regenerative Medicine
• RNA-Seq
• RNAi/siRNA
• Sequencing
• Small Molecules
• SNP/Genotyping
• Stem Cells
• Synthetic Biology
• Toxicity
• Transfection
• Vaccines
• Western Blot

GEN news highlights

• U.S. Drug Manufacturing Decline Reflects Wage Gap and Regulatory Scrutiny
  
• Moffitt Cancer Center, Sanford-Burnham, and Florida Hospital Forge Pact
  
• Illumina Shuns Roche’s $5.7 Bid, While Roche Prepares for the Long Haul
  
• Gedeon Richter, Forest Drug Cariprazine Succeeds in Third Phase III Bipoar Disorder Study
  
• FDA Okays Shire's ADHD Drug Vyvanse for Maintenance Therapy in Adults
  

• MORE BIOBUSINESS GEN NEWS HIGHLIGHTS

Insight & intelligence™

• U.S. Patent Law Retains Key Differences with Europe and Canada
  February 9, 2012
  Distinctions range from how patentability is determined to how prior user rights are defined.
• Full Results from Recent Survey of California Biopharma CEOs Highlight Frustrations
  February 8, 2012
  Companies are increasingly taking their business elsewhere, mostly due to financial constraints.
• EMA’s Draft Rules for Interferon Beta Biosimilars Include Clinical and Nonclinical Studies
  February 6, 2012
  Guidance is now open to comments, and a final rule is expected by the middle of this year.
• Collaborations Hold the Potential to Reinvent Drug Development
  February 2, 2012
  Big industry players are cutting their R&D budgets but cannot afford to stop R&D entirely.
• Despite Flat Budget, NIH’s TRND Program Tries to Spark Interest in Rare and Neglected Diseases
  January 31, 2012
  With 14 approved programs in total, TRND has progressed two into clinical development.

• MORE BIOBUSINESS INSIGHT & INTELLIGENCE™

Feature articles

• GEN's 30th Anniversary: Bacteria Combat Waste
  
• GEN's 30th Anniversary: Molecular Diagnostics
  
• GEN's 30th Anniversary: Peptide Therapeutics
  
• Can the FDA Be a Catalyst for Innovation?
  New Commissioner Realigning Programs to Better Support Core Functions and Responsibilities
• GEN's 30th Anniversary: HIV/AIDS
  

• MORE BIOBUSINESS FEATURE ARTICLES

Corporate profiles

• Sutro Aims to Improve Protein Synthesis
  Company Claims Its OCFS Method Makes Proteins that Traditional Systems Can’t Produce
• Serum Focus Gives Way to Complete Systems
  Thermo Scientific Unit Combines Media and Serum, Single-Use, and Customized Solutions
• Industrial Quantities of IPSCs Now Possible
  CDI Offers Stem Cell Products for Studies on Heart, Liver, CNS, and Endothelial Tissue
• Cell Growth Takes on New Dimension
  Nano-FM Is Bridging the Gap Between 2-D and 3-D Culture with Biodegradable Nanofibers
• Samsung Stakes Out Biopharma Position
  Firm Seeks to Replicate Success in Electronics Industry in Biopharmaceutical Manufacturing

• MORE BIOBUSINESS CORPORATE PROFILES

BioMarket trends

• Competition Intensifies among U.S. Clusters
  Various Cities Vie for More Talent to Meet Industry Demands
• Bioprocessors Enter Year on Optimistic Note
  2012 Budget Trends Indicate Recession-Proof Segment
• Biologics Fill Void in Arthritis Treatment
  Biologic Response Modifiers Dominate Market that Could Exceed $20B in 2011.
• Protein Purification Reagent Market Expands
  Role in Biopharmaceutical, Diagnostic, and Basic Biomedical Research Increases Usage
• Infectious Disease Molecular Diagnostics
  Market Review and Opportunities

• MORE BIOBUSINESS BIOMARKET TRENDS

Wall street biobeat

• Taking a Close Look at Big Pharma’s Future
  
• Shopping for Financing “At-the-Market”
  Alternate Option May Offer Huge Savings, as Conventional Methods Can Cost 10x More
• Funding Solutions for Life Science Startups
  Daunting Prospects Demand a Variety of Creative Financing Strategies
• Biotech Takes Hit from Jittery Market in Q3
  Debt Worries and Political Dysfunction Take Their Toll on Financing Activity in Sector
• Volatility Rattles Biotechnology Sector
  Uncertainty Will Continue Until Policy Makers Find Path to Sustainable Global Economic Stability

• MORE BIOBUSINESS WALL STREET BIOBEAT

BLOG biotech

• Business Criteria, Not Patriotism, Determine Manufacturing Decisions
  
• Whence Goeth NIH Investigators?
  
• Agbiotech Is Working to Help Plants Cope with Global Warming
  
• Chimps Get a Break
  
• Biotech in Brazil on the Rise
  

• VIEW BY SUBJECT | MORE BIOBUSINESS BLOG BIOTECH

GEN podcasts

• Disruptive Science and Technology: A New Journal
  Alan Russell, Ph.D., Editor in Chief
• Exploring Biotech’s Past and Predicting Its Future with G. Steven Burrill
  G. Steven Burrill, CEO, Burrill & Company
• Drug Repositioning as a Viable Business Model
  Aris Persidis, Ph.D., President, Biovista
• Nonsuppressive Drug Therapy for HIV
  Mark G. Fromhold, Ph.D., Vice President, Manufacturing & Business Development, Koronis Pharmaceuticals
• Presidential Commission’s Report on Synthetic Biology
  Drew Endy is an assistant professor of bioengineering at Stanford University. He earned a BS and MS in civil and environmental engineering, respectively, from Lehigh University and a Ph.D. in biochemical engineering from Dartmouth College.

• MORE BIOBUSINESS GEN PODCASTS

Webinars

• Supplier Webinars: Quality Control in Real Time—Accelerating Bioanalysis Workflows and Reducing QC Burden with IDBS
  

• MORE BIOBUSINESS WEBINARS

GEN polls

• FDA on Biosimilars
  
• California Biopharma Forecast
  
• Therapeutics for Rare and Neglected Diseases
  
• Biodefense in 2012
  
• NIH Scientists
  

• MORE BIOBUSINESS GEN POLLS

Events

• BIO CEO & Investor Conference
  2012 February 13 - February 14 New York, NY, UNITED STATES
• Biophysical Society Annual Meeting
  2012 February 25 - February 29 San Diego, CA, UNITED STATES
• AsiaTIDES
  2012 February 28 - March 1 Tokyo, , JAPAN
• X-GEN Congress & Expo
  2012 March 5 - March 8 San Diego, CA, UNITED STATES
• PITTCON
  2012 March 11 - March 15 Orlando, FL, UNITED STATES

• MORE BIOBUSINESS EVENTS

Home | Terms of Use | Privacy Statement | Legal